{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T17:36:59Z","timestamp":1793381819207,"version":"4.5.0"},"reference-count":43,"publisher":"CERN","license":[{"start":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T00:00:00Z","timestamp":1737676800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"The Swiss State Secretary for Education Research and Innovation"},{"name":"European Commission","award":["101103189"],"award-info":[{"award-number":["101103189"]}],"id":[{"id":"https:\/\/ror.org\/00k4n6c32","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Open Res Europe"],"abstract":"<jats:p>Background\n                    Coordinated efforts in the control of gambiense human African trypanosomiasis (gHAT) have significantly reduced its endemicity. WHO targets interruption of transmission by 2030. However, challenges remain, including low sensitivity of the current parasitological confirmation tests, leaving a potential human reservoir untreated. Acoziborole, a single-dose oral treatment, effective in both disease stages with a good safety profile, offers the potential of treatment of parasitologically negative gHAT seropositive subjects, which could improve diagnostic sensitivity. The STROGHAT study aims to evaluate whether this approach can lead to elimination of \n                        T.b. gambiense from its human reservoir, and to provide further safety data on acoziborole. It also includes a costing analysis and a prospective evaluation of the performance of the screening and diagnostic tests used.\n                \n                \n                    Methods\n                    STROGHAT is a one-arm epidemiological study, with a nested phase IIIb, one-arm, open label, non-randomized, multicentre clinical trial. It will be implemented over four years in the endemic region of the Equateur North, in the Democratic Republic of Congo. For the first three years, parasitologically negative gHAT seropositive subjects will be treated with acoziborole, while parasitologically confirmed cases will receive standard of care. Individual follow-up needs and accurate prevalence estimate will be based on immunological and molecular tests performed for all gHAT screening test seropositive subjects at a reference laboratory. In the fourth year, standard procedures will resume, and a prevalence survey will assess whether interruption of transmission has been achieved.\n                \n                \n                    Discussion\n                    The manuscript outlines the study background, objectives and methods while discussing its strengths and challenges. If successful, the STROGHAT study will provide critical evidence on the effectiveness, safety and feasibility of the new strategy, and inform future elimination strategies.\n                \n                \n                    Clinical trial registration\n                    \n                        NCT06356974. Date of registration: April 4, 2024.<\/jats:p>","DOI":"10.12688\/openreseurope.19077.1","type":"journal-article","created":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T11:00:13Z","timestamp":1737716413000},"update-policy":"https:\/\/doi.org\/10.68336\/openreseurope.updatepolicy","source":"Crossref","is-referenced-by-count":10,"title":["The STROGHAT study protocol: An intervention study to evaluate safety, effectiveness and feasibility of treating gambiense HAT seropositive subjects with acoziborole."],"prefix":"10.68336","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2870-0311","authenticated-orcid":true,"given":"Elena","family":"Nicco","sequence":"first","affiliation":[{"name":"Institute of Tropical Medicine Antwerp, Antwerp, 2000, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6795-0962","authenticated-orcid":true,"given":"Veerle","family":"Lejon","sequence":"additional","affiliation":[{"name":"French National Research Institute for Sustainable Development IRD, CIRAD, University of Montpellier, Montpellier, 34398, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erick","family":"Mwamba Miaka","sequence":"additional","affiliation":[{"name":"Programme National de Lutte contre la Trypanosomiase Humaine Africaine, Kinshasa, Democratic Republic of the Congo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5886-2004","authenticated-orcid":true,"given":"Dieudonn\u00e9","family":"Mumba","sequence":"additional","affiliation":[{"name":"Av. De la D\u00e9mocratie, Institut National de Recherche Biom\u00e9dicale, Kinshasa, Democratic Republic of the Congo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Mpanya","sequence":"additional","affiliation":[{"name":"Programme National de Lutte contre la Trypanosomiase Humaine Africaine, Kinshasa, Democratic Republic of the Congo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Kambo","sequence":"additional","affiliation":[{"name":"Programme National de Lutte contre la Trypanosomiase Humaine Africaine, Kinshasa, Democratic Republic of the Congo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Digas","family":"Ngolo","sequence":"additional","affiliation":[{"name":"Drugs for Neglected Diseases initiative Kinshasa, Kinshasa, Democratic Republic of the Congo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilfried","family":"Mutombo","sequence":"additional","affiliation":[{"name":"Drugs for Neglected Diseases initiative Kinshasa, Kinshasa, Democratic Republic of the Congo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Hugonnet","sequence":"additional","affiliation":[{"name":"Drugs for Neglected Diseases initiative, Geneva, Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Rembry","sequence":"additional","affiliation":[{"name":"Drugs for Neglected Diseases initiative, Geneva, Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig","family":"Tipple","sequence":"additional","affiliation":[{"name":"Drugs for Neglected Diseases initiative, Geneva, Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"Inocencio Da Luz","sequence":"additional","affiliation":[{"name":"Institute of Tropical Medicine Antwerp, Antwerp, 2000, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rian","family":"Snijders","sequence":"additional","affiliation":[{"name":"Institute of Tropical Medicine Antwerp, Antwerp, 2000, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catiane","family":"Vander Kelen","sequence":"additional","affiliation":[{"name":"Institute of Tropical Medicine Antwerp, Antwerp, 2000, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stijn","family":"Rog\u00e9","sequence":"additional","affiliation":[{"name":"Institute of Tropical Medicine Antwerp, Antwerp, 2000, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick","family":"Van Reet","sequence":"additional","affiliation":[{"name":"Institute of Tropical Medicine Antwerp, Antwerp, 2000, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Tarral","sequence":"additional","affiliation":[{"name":"Independent Consultant, Geneva, 1202, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Verl\u00e9","sequence":"additional","affiliation":[{"name":"Independent Consultant, Antwerp, 2000, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Epco","family":"Hasker","sequence":"additional","affiliation":[{"name":"Institute of Tropical Medicine Antwerp, Antwerp, 2000, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"13904","published-online":{"date-parts":[[2025,1,24]]},"reference":[{"key":"69524","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2011.03536.x"},{"key":"69525","doi-asserted-by":"publisher","DOI":"10.1016\/j.pt.2017.11.008"},{"key":"69526","doi-asserted-by":"publisher","DOI":"10.1186\/1476-072X-9-57"},{"key":"69527","unstructured":"4. WHO: Control and surveillance of human African trypanosomiasis: WHO TRS N\u00b0984. Reference Source (https:\/\/www.who.int\/trypanosomiasis_african\/resources\/who_trs_984\/en\/2014)"},{"key":"69528","unstructured":"5. Simarro PP, Sima FO, Mir M, et al.: [Control of human African trypanosomiasis in Luba in equatorial Guinea: evaluation of three methods]. Bull World Health Organ. 1991; 69(4): 451\u20137. https:\/\/pubmed.ncbi.nlm.nih.gov\/1934239 https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/2393243"},{"key":"69529","unstructured":"6. WHO: Criteria and procedures for the verification of elimination of transmission of T. b. gambiense to the human population in a given country. 2023. Reference Source (https:\/\/iris.who.int\/bitstream\/handle\/10665\/373875\/9789240075559-eng.pdf?sequence=1)"},{"key":"69530","unstructured":"7. WHO: Ending the neglect to attain the sustainable development goals. A road map for neglected tropical diseases 2021-2030. 2020. Reference Source (https:\/\/www.eliminateschisto.org\/sites\/gsa\/files\/content\/attachments\/2020-06-10\/WHO_Revised-Draft-NTD-Roadmap2021-2030-23Apr2020.pdf)"},{"key":"69531","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-3156.2004.01240.x"},{"key":"69532","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-3156.2006.01624.x"},{"key":"69533","doi-asserted-by":"publisher","DOI":"10.3390\/tropicalmed5010029"},{"key":"69534","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-158-3-201302050-00583"},{"key":"69535","unstructured":"12. Nicco E: SPIRIT checklist STROGHAT (1.0). Zenodo.2024."},{"key":"69536","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0006890"},{"key":"69537","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0008261"},{"key":"69538","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0012111"},{"key":"69539","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0010047"},{"key":"69540","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0000471"},{"key":"69541","unstructured":"18. WHO. World Health Organization: Guidelines for the treatment of human African trypanosomiasis. 2024. Reference Source (https:\/\/iris.who.int\/bitstream\/handle\/10665\/378083\/9789240096035-eng.pdf)"},{"key":"69542","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0009656"},{"key":"69543","doi-asserted-by":"publisher","DOI":"10.1016\/0001-706x(95)00127-z"},{"key":"69544","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0258711"},{"key":"69545","doi-asserted-by":"publisher","DOI":"10.1186\/s40249-024-01220-5"},{"key":"69546","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-3156.2012.03042.x"},{"key":"69547","unstructured":"24. Magnus E, Vervoort T, Van Meirvenne N: A Card-Agglutination Test with stained Trypanosomes (C.A.T.T.) for the serological diagnosis of T. B. gambiense trypanosomiasis. Ann Soc Belg Med Trop. 1978; 58(3): 169\u201376. https:\/\/pubmed.ncbi.nlm.nih.gov\/747425"},{"key":"69548","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(14)70203-7"},{"key":"69549","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa1264"},{"key":"69550","doi-asserted-by":"publisher","DOI":"10.1051\/parasite\/2022024"},{"key":"69551","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.2010.09-0735"},{"key":"69552","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0009407"},{"key":"69553","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics12020246"},{"key":"69554","unstructured":"31. European Medicines Agency (EMA): ICH E2A Clinical safety data management: definitions and standards for expedited reporting - Scientific guideline.1995; [25 October, 2023]. Reference Source (https:\/\/www.ema.europa.eu\/en\/ich-e2a-clinical-safety-data-management-definitions-standards-expedited-reporting-scientific-guideline)"},{"key":"69555","unstructured":"32. Common Terminology Criteria for Adverse Events (CTCAE): Protocol Development. CTEP (cancer.gov). Reference Source (https:\/\/ctep.cancer.gov\/protocoldevelopment\/)"},{"key":"69556","unstructured":"33. WMA: WMA Declaration of Helsinki-Ethical principles for medical research involving human participants.2024. Reference Source (https:\/\/www.wma.net\/policies-post\/wma-declaration-of-helsinki\/)"},{"key":"69557","doi-asserted-by":"publisher","DOI":"10.5281\/zenodo.14500360"},{"key":"69558","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0001467"},{"key":"69559","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-3156.2006.01768.x"},{"key":"69560","doi-asserted-by":"publisher","DOI":"10.1186\/s13071-015-1131-8"},{"key":"69561","doi-asserted-by":"publisher","DOI":"10.2471\/BLT.23.290172"},{"key":"69562","doi-asserted-by":"publisher","DOI":"10.1186\/s40249-023-01076-1"},{"key":"69563","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0004608"},{"key":"69564","doi-asserted-by":"publisher","DOI":"10.2471\/BLT.23.290176"},{"key":"69565","unstructured":"42. WHO: Human African Trypanosomiasis Atlas."},{"key":"69566","doi-asserted-by":"publisher","DOI":"10.1097\/QCO.0000000000000860"}],"container-title":["Open Research Europe"],"original-title":[],"link":[{"URL":"https:\/\/open-research-europe.ec.europa.eu\/articles\/5-23\/v1\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ore.eu\/ore\/article\/download\/821\/version\/1430\/2857","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ore.eu\/ore\/article\/download\/821\/version\/1430\/2858","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ore.eu\/ore\/article\/download\/821\/version\/1430\/2857","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T17:12:56Z","timestamp":1793380376000},"score":1,"resource":{"primary":{"URL":"https:\/\/ore.eu\/ore\/article\/view\/821\/version\/1430"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,24]]},"references-count":43,"URL":"https:\/\/doi.org\/10.12688\/openreseurope.19077.1","relation":{"has-review":[{"id-type":"doi","id":"10.21956\/openreseurope.20642.r52017","asserted-by":"object"},{"id-type":"doi","id":"10.21956\/openreseurope.20642.r50336","asserted-by":"object"}]},"ISSN":["2732-5121"],"issn-type":[{"value":"2732-5121","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,24]]},"assertion":[{"value":"2025-01-24","name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}},{"value":"This project has received funding from the European Union\u2019s Horizon Europe research and innovation programme, Global Health EDCTP3 under grant agreement No. 101103189. Project name: Stop Transmission of gambiense Human African Trypanosomiasis (STROGHAT). The project has also received complementary funding from the Swiss State Secretary for Education Research and Innovation (SERI), Switzerland. The findings and conclusions contained herein are those of the authors and do not necessarily reflect positions or policies of the aforementioned funding bodies.\n\n                    The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.","name":"funding_statement","label":"Funding Statement","group":{"name":"funding_information","label":"Funding Information"}}],"article-number":"23"}}